Orlifat Capsule contains Orlistat 60 mg, a potent lipase inhibitor indicated for the management of obesity. It acts locally in the gastrointestinal tract by inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By blocking these enzymes, Orlistat reduces the absorption of dietary fat by approximately 30%, thereby promoting weight loss in conjunction with a reduced-calorie diet. Orlifat is prescribed for adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² in the presence of other risk factors such as hypertension, diabetes, or dyslipidemia. The medication is typically administered orally at a dose of 60 mg three times daily with each main meal containing fat. Common adverse effects include gastrointestinal symptoms such as oily spotting, flatulence with discharge, fecal urgency, and increased defecation, which often diminish with continued use and adherence to a low-fat diet. Orlifat is contraindicated in patients with chronic malabsorption syndrome, cholestasis, or hypersensitivity to Orlistat. It is essential to monitor fat-soluble vitamin levels during prolonged therapy, as Orlistat may impair their absorption. This medication should be used under medical supervision as part of a comprehensive weight management program.